NCT00532415

Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy

Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.

Conditions

• Vitrectomy

Interventions

Type	Name	Description
DRUG	Triamcinolone Acetonide Injectable Suspension	Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.

Timeline

• Start date: 2007-09-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2007-09-20
• Last updated: 2012-04-05